The emergence of FR during anti–IL-4/IL-13 therapy underscores the need for careful differential diagnosis (ACD, Malassezia hypersensitivity, alcohol-induced facial flushing) and tailored therapeutic interventions ranging from topical agents to systemic switches [51,52,54]. Here, IL13 is linked to granular corneal dystrophy type II.